The whistleblower in a lawsuit accusing Medtronic (NYSE:MDT) of marketing its insulin pumps for off-label uses and running a kickbacks scheme to drive new sales withdrew some state claims from the case.
Former sales rep Adam Witkin alleged in 2011 that Medtronic offered “false and misleading” information on the off-label use of high-concentration U-500 insulin with its insulin pumps, and of using a kickbacks scheme to induce doctors to prescribe its insulin pumps.
